Platform
- DefiniGEN Ulti-HEP
Applications
- Efficacy Screening
- Toxicology Screening
- Disease Modeling
- Gene Editing Services
Cell Products
Wild-type cells
Disease Models
About
- About us
- Career Opportunities
News
- News
- Blog
Events
- View all events
Resources
- Resources
- Blogs

Contact

Platform
- DefiniGEN Ulti-HEP
Applications
- Efficacy Screening
- Toxicology Screening
- Disease Modeling
- Gene Editing Services
Cell Products
Wild-type cells
Disease Models
About
- About us
- Career Opportunities
News
- News
- Blog
Events
- View all events
Resources
- Resources
- Blogs

Contact

News

Read about our latest company news, including information on product releases, grant awards, conference attendances, and more!

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

Jun 3, 2024 9:00:00 AM

DefiniGEN achieves Cyber Essentials certification

Sep 12, 2023 9:00:00 AM

DefiniGEN secures ISO 9001:2015 recertification

Jul 26, 2023 9:00:00 AM

DefiniGEN secures ISO 9001:2015 recertification

Jul 23, 2023 9:00:00 AM

DefiniGEN Achieves ISO 9001: (2015) Certification

Jun 13, 2023 9:00:00 AM

The FDA Modernization Act 2.0

Jun 13, 2023 9:00:00 AM

DefiniGEN appoints Dr Chris Kirton as Chief Executive Officer

Jan 20, 2022 9:00:00 AM

Enabling cures for liver disease through highly predictive in vitro modelling

Screening

Efficacy Screening
Toxicology Screening
Disease Modeling

Platform

UltiDIFF Platform
Cell Based Products

Knowledge

About Us
Contact Us
Resources
Blog

DefiniGEN Ltd. has been assessed and approved to ISO 9001:2015 Quality Management System.

Proud member of the 3Rs Collaborative’s Microphysiological Systems initiative.

Green Impact Silver Award winning organization.

Privacy Policy | Terms & Conditions

Copyright © 2025 DefiniGEN Limited All rights reserved